# Intervention Insights

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intervention-insights

- Industry: Healthcare
- Headquarters: Burlington, US
- Website: www.trapelohealth.com
- Total disclosed funding: $11M
- Latest round: Series B (Jul 9, 2014)
- Investors on record: 4

## About

Intervention Insights, Inc. is a US-based company specializing in precision medicine solutions. They provide an interoperable platform that assists healthcare professionals in making evidence-based decisions for oncology treatment.Founded in 2009 in Burlington, US, Intervention Insights, Inc. focuses on enhancing treatment decisions in oncology through their innovative platform. The company was recently acquired by NeoGenomics, Inc. for USD 65 mn on March 24, 2021. The firm has executed a total of 5 deals throughout its history under the leadership of CEO Clynt Taylor.Trapelo Health, a product of Intervention Insights, Inc., offers a pioneering decision-support platform tailored for oncologists, laboratories, and health payers. This platform streamlines clinical workflows and manages prior authorization, ensuring patients receive timely, evidence-supported treatment options while enhancing access to precision therapies and clinical trials across the United States.The company employs a B2B model, engaging healthcare providers, labs, and insurers through partnerships and subscriptions for access to its platform and related services. Revenue is structured around contracted agreements, which may involve tiered pricing based on service usage, aligning its offerings directly with oncologists' needs to improve patient outcomes.Following the recent acquisition by NeoGenomics, Inc., Intervention Insights, Inc. plans to leverage the USD 65 mn funding to enhance its product offerings and expand into new markets. This includes the development of new features for their platform to better serve oncology professionals. The company aims to broaden its reach in the healthcare sector by targeting additional regions across the United States in the coming years.

## Funding rounds

- Series B, Jul 9, 2014, $3.5M — Chrysalis Ventures
- Series B, Jul 18, 2011, $7.2M — Chrysalis Ventures, Beringea, Hopen Life Science Ventures, Charter Capital Partners

## Investors

- Chrysalis Ventures (https://capitalatlas.ai/funds/chrysalis-ventures) — Series B
- Beringea (https://capitalatlas.ai/funds/beringea) — Series B
- Hopen Life Science Ventures (https://capitalatlas.ai/funds/hopen-life-science-ventures) — Series B
- Charter Capital Partners (https://capitalatlas.ai/funds/charter-capital-partners) — Series B